-
1
-
-
0141729306
-
Practical pharmacovigilance analysis strategies
-
Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003; 12: 559-74
-
(2003)
Pharmacoepidemiol Drug Saf
, vol.12
, pp. 559-74
-
-
Gould, A.L.1
-
2
-
-
26944491481
-
Perspectives on the use of data mining in pharmacovigilance
-
Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf 2005; 28 (11): 981-1007
-
(2005)
Drug Saf
, vol.28
, Issue.11
, pp. 981-1007
-
-
Almenoff, J.1
Tonning, J.M.2
Gould, A.L.3
-
3
-
-
78549259368
-
-
EMEA Eudravigilance Expert Working Group (EV-EWG) 26 June London. Doc. Ref. EMEA/106464/2006 rev.1 [online]. Available Accessed 2010 Sep 6
-
EMEA Eudravigilance Expert Working Group (EV-EWG). Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system, 26 June 2008. London. Doc. Ref. EMEA/106464/2006 rev.1 [online]. Available from URL http://www.ema.europa.eu/docs/en- GB/document-library/ Regulatory-and-procedural-guide line/2009/11/WC500011434.pdf [Accessed 2010 Sep 6].
-
(2008)
Guideline on the Use of Statistical Signal Detection Methods in the Eudravigilance Data Analysis System
-
-
-
4
-
-
24344432126
-
The role of data mining in pharmacovigilance
-
Sep
-
Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005 Sep; 4 (5): 929-48
-
(2005)
Expert Opin Drug Saf
, vol.4
, Issue.5
, pp. 929-48
-
-
Hauben, M.1
Madigan, D.2
Gerrits, C.M.3
-
5
-
-
52449124309
-
The importance of reporting negative findings in data mining: The example of exenatide and pancreatitis
-
Hauben M, Hochberg A. The importance of reporting negative findings in data mining: the example of exenatide and pancreatitis. Pharmaceut Med 2008; 22 (4): 215-9
-
(2008)
Pharmaceut Med
, vol.22
, Issue.4
, pp. 215-9
-
-
Hauben, M.1
Hochberg, A.2
-
6
-
-
73649129173
-
Quantitative signal detection for vaccines: Effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports database
-
Zeinoun Z, Seifert H, Verstraeten T. Quantitative signal detection for vaccines: effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports database. Hum Vaccines 2009; 5 (9): 599-607
-
(2009)
Hum Vaccines
, vol.5
, Issue.9
, pp. 599-607
-
-
Zeinoun, Z.1
Seifert, H.2
Verstraeten, T.3
-
7
-
-
60749099873
-
Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions
-
Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32 (2): 99-110
-
(2009)
Drug Saf
, vol.32
, Issue.2
, pp. 99-110
-
-
Hauben, M.1
Aronson, J.K.2
-
8
-
-
33644926443
-
Response to letter by Levine et al
-
Hauben M, Reich L. Response to letter by Levine et al. Br J Clin Pharmacol 2005; 61 (1): 115-7
-
(2005)
Br J Clin Pharmacol
, vol.61
, Issue.1
, pp. 115-7
-
-
Hauben, M.1
Reich, L.2
-
9
-
-
35148890461
-
Using data mining to predict safety actions from FDA adverse event reporting system data
-
Hochberg AM, Reisinger SJ, Pearson RK, et al. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J 2007; 41 (5): 633-44
-
(2007)
Drug Inf J
, vol.41
, Issue.5
, pp. 633-44
-
-
Hochberg, A.M.1
Reisinger, S.J.2
Pearson, R.K.3
-
10
-
-
77953568356
-
A decade of data mining and still counting
-
Hauben M, Noren GN. A decade of data mining and still counting. Drug Saf 2010; 33 (7): 527-34
-
(2010)
Drug Saf
, vol.33
, Issue.7
, pp. 527-34
-
-
Hauben, M.1
Noren, G.N.2
-
11
-
-
34548700834
-
Data mining in pharmacovigilance: Computational cost as a neglected performance parameter
-
Hauben M, Madigan D, Hochberg AM, et al. Data mining in pharmacovigilance: computational cost as a neglected performance parameter. Int J Pharm Med 2007; 21 (5): 319-23
-
(2007)
Int J Pharm Med
, vol.21
, Issue.5
, pp. 319-23
-
-
Hauben, M.1
Madigan, D.2
Hochberg, A.M.3
-
12
-
-
78549296716
-
Large scale regressionbased pattern discovery: The example of screening the WHO global drug safety data base
-
Caster O, Noren GK, Madigan D, et al. Large scale regressionbased pattern discovery: the example of screening the WHO global drug safety data base. Stat Anal Data Min 2010; 3 (4): 197-208
-
(2010)
Stat Anal Data Min
, vol.3
, Issue.4
, pp. 197-208
-
-
Caster, O.1
Noren, G.K.2
Madigan, D.3
-
13
-
-
34748847390
-
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias
-
Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30 (10): 891-8
-
(2007)
Drug Saf
, vol.30
, Issue.10
, pp. 891-8
-
-
Pariente, A.1
Gregoire, F.2
Fourrier-Reglat, A.3
-
14
-
-
34249896410
-
'Extreme duplication' in the US FDA Adverse Events Reporting System Database
-
Hauben M, Reich L, DeMicco J, et al. 'Extreme duplication' in the US FDA Adverse Events Reporting System Database. Drug Saf 2007; 30 (6): 551-4
-
(2007)
Drug Saf
, vol.30
, Issue.6
, pp. 551-4
-
-
Hauben, M.1
Reich, L.2
Demicco, J.3
-
15
-
-
34548644680
-
Interexpert agreement of seven criteria in causality assessment of adverse drug reactions
-
Oct
-
Arimone Y, Miremont-Salame G, Haramburu F, et al. Interexpert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol 2007 Oct; 64 (4): 482-8
-
(2007)
Br J Clin Pharmacol
, vol.64
, Issue.4
, pp. 482-8
-
-
Arimone, Y.1
Miremont-Salame, G.2
Haramburu, F.3
-
16
-
-
0142244575
-
Omeprazole-induced intractable cough
-
Howalzi M, Delafosse C. Omeprazole-induced intractable cough. Ann Pharmacother 2003; 37: 1607-9
-
(2003)
Ann Pharmacother
, vol.37
, pp. 1607-9
-
-
Howalzi, M.1
Delafosse, C.2
|